Recent developments include preclinical study results on Telomir-1, equity funding rounds, management appointments, and plans for regulatory filings and presentations.

• Telomir announced preclinical results on Telomir-1, including confirmation of copper binding capabilities and reversal of key parameters of type 2 diabetes in preclinical studies [N6][N12][N13].
• The company raised $1 million in equity funding and entered into a stock purchase agreement for $1 million in December 2024 [N7][N11].
• Telomir plans to present at BIO 2025 and pursue an IND filing for Telomir-1 [N3].
• Erez Aminov was appointed CEO in August 2024 [N14].
• Telomir announced findings from a preclinical progeria lifespan study in January 2025 [N5].
• The company's stock experienced after-hours trading jumps on light news flow and select updates in October 2025 [N2].
• Telomir was mentioned among sector laggards in drugs and oil & gas exploration stocks in October 2025 [N1].

Telomir has demonstrated progress in preclinical studies of Telomir-1, including findings on copper binding and effects on type 2 diabetes parameters, which may support further development. The company has secured equity funding and entered into stock purchase agreements to support operations. Plans to present at BIO 2025 and pursue an IND filing indicate active advancement toward clinical development. Exclusive licensing rights in North America provide a pathway for potential commercialization if regulatory approvals are obtained.

Telomir faces significant risks including dependence on a license for intellectual property it does not own, with limited control over patent prosecution and potential loss of rights. The company has no revenues and a history of net losses, with liquidity sufficient only into early 2027, necessitating additional financing that may not be available on favorable terms. Management operates on a part-time basis, which may impact operational effectiveness. The pharmaceutical sector is highly competitive, and the early development stage of Telomir-1 means regulatory approval and commercialization are uncertain. Operational fluctuations and reliance on third-party manufacturers add further risk.

Telomir's potential competitive advantage lies in its exclusive license to Telomir-1 in North America and its focus on novel pharmaceutical development. However, the company does not own the underlying intellectual property, which is controlled by MIRALOGX LLC, limiting its control over patent prosecution and enforcement. The pharmaceutical industry is highly competitive, with larger companies possessing greater resources and established market presence. The complexity and uncertainty of patent protection in this field, combined with reliance on third-party manufacturing and the early development stage of Telomir-1, constrain the company's moat.

• Intellectual Property Risks: Telomir does not own the intellectual property rights to Telomir-1 and relies on a license from MIRALOGX LLC. The company has limited control over patent prosecution and enforcement, which may affect its ability to protect and commercialize its product candidate. Breach of license terms or failure to pay royalties could result in loss of rights.
• Financial and Liquidity Risks: The company has no revenues and has incurred significant net losses, with liquidity sufficient to fund operations only into early 2027. Additional financing will be required to continue development, and failure to secure such funding could force curtailment or cessation of operations.
• Operational Risks: Management operates on a part-time basis, which may affect availability and responsiveness. The company relies on third-party manufacturers for production, which introduces risks related to supply, quality, and timing.
• Competitive Risks: Telomir operates in a highly competitive pharmaceutical industry with larger, more established companies. Competitors may develop safer, more effective, or less expensive treatments, potentially limiting Telomir's market opportunities.
• Regulatory and Development Risks: Significant additional research, preclinical testing, and clinical trials are required before Telomir-1 can achieve regulatory approval. The development process is lengthy, costly, and uncertain.

• Telomir Pharmaceuticals, Inc. is an early development-stage pharmaceutical company focused on the development of a pre-clinical product candidate named Telomir-1 [S1].
• Telomir-1 is licensed exclusively from MIRALOGX LLC, which owns the underlying intellectual property and patent applications; Telomir does not own these rights [S1].
• The license grants Telomir exclusive rights to develop and commercialize Telomir-1 in the United States, Mexico, and Canada, with MIRALOGX retaining rights outside these territories [S1].
• Telomir is required to pay MIRALOGX an 8% royalty on net sales of Telomir-1, with a minimum annual royalty of $250,000 starting from the first revenue year [S1].
• The company depends on the successful development, regulatory approval, and commercialization of Telomir-1, which remains in preclinical stages and requires significant further research and clinical testing [S1].
• Telomir has no revenues to date and has incurred significant net losses, with an accumulated deficit of $41.0 million as of December 31, 2025 [S1].
• As of June 30, 2025, Telomir had cash and cash equivalents of approximately $754,323 USD and current assets of about $5.37 million USD as of June 30, 2026, with current liabilities of approximately $332,424 USD, resulting in a strong current ratio of 16.14 and a cash ratio of 2.27 [S2].
• The company’s existing capital is sufficient to fund operations and planned initial clinical development activities into the first quarter of 2027, but additional financing will be required thereafter [S1].
• Telomir’s CEO, Erez Aminov, and CFO, Alan Weichselbaum, are part-time employees, which may affect availability and management focus [S1].
• The company relies on third-party manufacturers for production of Telomir-1 and does not own manufacturing facilities [S1].
• There are risks related to intellectual property, including lack of control over patent prosecution by MIRALOGX, potential loss of license rights, and exposure to infringement claims [S1].
• Telomir faces intense competition from larger pharmaceutical and biotechnology companies with greater resources and experience [S1].
• The company’s operating results may fluctuate significantly due to factors such as clinical trial progress, research and development expenses, and contract manufacturing costs [S1].
• Telomir has announced preclinical results on Telomir-1, including findings related to copper binding capabilities and effects on type 2 diabetes parameters in preclinical studies [N6][N12][N13].
• The company raised $1 million in equity funding in December 2024 and entered into a stock purchase agreement for $1 million around the same time [N7][N11].
• Telomir plans to present at BIO 2025 and is pursuing an IND filing for Telomir-1 [N3].
• The company announced findings from a preclinical progeria lifespan study in January 2025 [N5].
• Telomir’s stock experienced after-hours trading jumps on light news flow and select updates in October 2025 [N2].
• The company appointed Erez Aminov as CEO in August 2024 [N14].
• Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice [S2].